Entropy Neurodynamics Limited (ASX: ENP) - Share Price

Current share price for ENP : $0.036 0.002 (5.88%)⁺

Entropy Neurodynamics Limited (ENP, formerly Tryptamine Therapeutics Limited), an ASX-listed company,, is a clinical-stage biotechnology company focused on developing patented, original formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs.

ENP General Information ⁺

ASX Code	ENP
Website	http://www.tryptherapeutics.com
Industry/Sector	Pharmaceuticals
Market Cap ($M)	58
ENP Share Price	$0.036
Day High	$0.036
Day Low	$0.036
Last Close	$0.034
ENP Share Price Movement	$0.00 ( 5.88% )

Prices as at 16:36, 22 Jul 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

Entropy Neurodynamics Limited (ENP) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from Entropy Neurodynamics Limited (ENP) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Entropy Neurodynamics Limited (ENP) price-sensitive announcements

ENP - South Africa Grants ENP Broad Fibromyalgia Patent to 2043

Entropy Neurodynamics Limited announced that it has been granted a South African patent co

Entropy Neurodynamics Limited (ENP)
20 Jul 2026 | 8:35 AM

ENP - 100% Clinical improvement, 50% Remission in BED study

Entropy Neurodynamics Limited announced groundbreaking results from their Phase 2 trial of

Entropy Neurodynamics Limited (ENP)
7 Jul 2026 | 9:37 AM

ENP - Trading Halt

Entropy Neurodynamics Limited has requested a trading halt for its ordinary shares on the

Entropy Neurodynamics Limited (ENP)
3 Jul 2026 | 9:09 AM

ENP - DSMB Clears TRP 8803 to Advance to Cohort 2

Entropy Neurodynamics Limited announced the progression of its TRP-8803 program for Binge

Entropy Neurodynamics Limited (ENP)
15 Jun 2026 | 9:55 AM

Entropy Neurodynamics Limited (ENP) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
Entropy Neurodynamics Limited (ENP) ORDINARY FULLY PAID	Health Care	$59	Quarterly Activities Report and Appendix 4C	22 Jul 2026 8:26AM	$0.034	$0.036	risen by 5.88%
Entropy Neurodynamics Limited (ENP) ORDINARY FULLY PAID	Health Care	$59	South Africa Grants ENP Broad Fibromyalgia Patent to 2043	20 Jul 2026 8:35AM	$0.036	$0.036	fallen by 0%
Entropy Neurodynamics Limited (ENP) ORDINARY FULLY PAID	Health Care	$59	Additional Australian patent granted	10 Jul 2026 9:07AM	$0.034	$0.036	risen by 5.88%
Entropy Neurodynamics Limited (ENP) ORDINARY FULLY PAID	Health Care	$59	Investor Presentation	9 Jul 2026 11:13AM	$0.034	$0.036	risen by 5.88%
Entropy Neurodynamics Limited (ENP) ORDINARY FULLY PAID	Health Care	$59	100% Clinical improvement, 50% Remission in BED study	7 Jul 2026 9:37AM	$0.032	$0.036	risen by 12.50%
Entropy Neurodynamics Limited (ENP) ORDINARY FULLY PAID	Health Care	$59	Trading Halt	3 Jul 2026 9:09AM	$0.032	$0.036	risen by 12.50%

ENP Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2025A	-$5.19	-$0.40	-56.30%	0.00%	0.0%
2024A	-$4.39	-$0.90	-76.00%	0.00%	0.0%
2023A	-$7.13	-$3.60	-43.60%	0.00%	0.0%

ENP Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A
Clarity Pharmaceuticals Ltd (CU6)	$866M	0.3002	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Entropy Neurodynamics Limited (ENP)	$58M	-0.5632	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%
Neuren Pharmaceuticals Limited (NEU)	$2,149M	-0.7857	0.0743	1.2000	72.8406	67.8000	30.8182	0.00%	0.00%	0.00%

ENP Market Comparison

	Earnings	P/E Ratio	P/B Ratio	P/E Growth
Company	0.00	0.00	8.29	0.00
Market	0.31	12.80	1.12	0.58
Sector	0.45	28.10	2.37	1.83

ENP Directors

Name	Position	Start Date
Dr Ian Edward Dixon	Chief Executive Officer	15 May 2013
Mr Christopher Ntoumenopoulos	Executive Director	1 May 2024
Mr Herwig Janssen	Non-Executive Chairman, Non-Executive Director	12 May 2025
Dr Daniel Tillett	Non-Executive Director	8 Nov 2024
Mr Jason Alan Carroll	Non-Executive Director	1 May 2024
Mr Gage Jull	Non-Executive Director	1 May 2024

Entropy Neurodynamics Limited (ENP) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
13 May 2026	CARROLL, Jason	Buy	Direct Shares	538,236	$0.036	$19,376.000
12 May 2026	CARROLL, Jason	Buy	Direct Shares	750,000	$0.035	$26,250.000
17 Apr 2026	JANSSEN, Herwig	Issued	Direct Shares	726,195	$0.034	$25,000.000

See all changes in directors' interest & trades for Entropy Neurodynamics Limited (ENP) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

ENP Management

Name	Position
Hamish George	Company Secretary
Jim Gilligan	President and Chief Scientific Officer

ENP Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Entropy Neurodynamics Limited (ENP). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
157,900,000 (11.36%)	William Garner
92,315,409 (6.64%)	Citicorp Nominees Pty Limited

ENP Calendar of Events

Date	Event
26 February 2027	Report (Interim)
28 August 2026	Report (Annual)
28 August 2026	Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us